HeartSciences Inc. (HSCS)
HeartSciences Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Southlake, TX, US. The stock last traded at $2.01, down 1.95% on the session, giving a market capitalisation of $4.3M. On trailing twelve-month figures it carries a trailing P/E of -0.51, a net margin of -211666.5%. Its beta of 1.80 implies it has historically moved more than the broad market.
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
HeartSciences Inc. is most often compared with the following Healthcare names: